-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Vnxf2FlKoxLZ3JLPozJ04DFQxFGrWG8abnAmF7wJ1okipTljKRoJVpPdHwGuoqmr ml8Jd71cGRuXbROd/EkxrA== 0000950144-05-012887.txt : 20051220 0000950144-05-012887.hdr.sgml : 20051220 20051219205830 ACCESSION NUMBER: 0000950144-05-012887 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051219 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20051220 DATE AS OF CHANGE: 20051219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMSURG CORP CENTRAL INDEX KEY: 0000895930 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 621493316 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22217 FILM NUMBER: 051274071 BUSINESS ADDRESS: STREET 1: 20 BURTON HILLS BLVD STREET 2: STE 350 CITY: NASHVILLE STATE: TN ZIP: 37215 BUSINESS PHONE: 6156651283 MAIL ADDRESS: STREET 1: ONE BURTON HILLS BLVD. STREET 2: SUITE 350 CITY: NASHVILLE STATE: TN ZIP: 37215 8-K 1 g98895e8vk.htm AMSURG CORP. - FORM 8-K AMSURG CORP. - FORM 8-K
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2005 (December 19, 2005)
AMSURG CORP.
(Exact Name of Registrant as Specified in Charter)
         
Tennessee
(State or Other Jurisdiction of
Incorporation) 		  000-22217
(Commission
File Number) 		  62-1493316
(I.R.S. Employer
Identification No.)
         
20 Burton Hills Boulevard
Nashville, Tennessee
    
37215
(Address of Principal Executive Offices)
   (Zip Code)
(615) 665-1283
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01.   Regulation FD Disclosure
     On December 19, 2005, the United States House of Representatives approved the conference report on The Deficit Reduction Act of 2005, which, among other actions, proposes beginning in 2007 to limit Medicare reimbursement for procedures performed at ambulatory surgery centers to those amounts provided by the Medicare OPD fee schedule. The conference report has not been considered by the United States Senate, and there can be no assurance that the conference report will be approved by the Senate or signed by the President in its current form.
     If approved by the Senate in its current form and signed into law, the conference report would negatively impact the reimbursement of after-cataract laser surgery procedures performed at the Company’s ophthalmology surgery centers. The Company’s ophthalmology surgery centers are currently reimbursed by Medicare at approximately $150 per procedure above the current Medicare OPD fee schedule amount. Based on the Company’s current Medicare volume of after-cataract laser surgery procedures, the Company’s current reimbursement rate for those procedures, and the current Medicare OPD fee schedule amount, the Company estimates that the reduced Medicare reimbursement would negatively impact the Company’s earnings per share in 2007 by approximately $0.02. The Company believes that the after-cataract laser surgery procedure is the only procedure performed in significant numbers in the Company’s surgery centers for which the current reimbursement rate exceeds the Medicare OPD fee schedule amount.

2

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  AMSURG CORP.
 		  
  By:   /s/ Claire M. Gulmi    
    Claire M. Gulmi
 		  
    Senior Vice President and Chief Financial Officer
(Principal Financial and Duly Authorized Officer) 		  
 
Date: December 20, 2005

3

-----END PRIVACY-ENHANCED MESSAGE-----